Humana (NYSE:HUM) 2026 Conference Summary Company Overview - **Company**: Humana Inc. - **Industry**: Healthcare and Medicare Advantage Key Themes and Commitments - Humana reaffirmed its commitment to achieving a stable Medicare Advantage (MA) margin of at least 3% and restoring earnings power by 2028, as stated during the Investor Day in June 2025 [2][3] - Adjustments to benefits will be necessary to accommodate the current medical cost trends and funding environment [3][12] Lifetime Value of Members - The concept of lifetime value is emphasized, indicating that the economic value of a member increases significantly from year one to year two, primarily due to lower retention costs and better member management [3][4] - A stable MA margin is essential for maximizing member retention and minimizing attrition [4][5] Membership Metrics - During the Annual Enrollment Period (AEP), over 1 million new members were added, with approximately 70% being switchers from other plans, which are generally more economically favorable in the first year [17][18] - Humana absorbed about 12% of plan exits, indicating a positive mix of new members coming from other plans rather than exits [18][19] - 70% of new members are enrolled in four-star or better contracts, and 75% are acquired through higher-quality sales channels [18][19] Sales Channel Strategy - Humana has focused on improving the quality of its sales channels by trimming lower-performing call centers and broker partners, which has led to a better membership mix [22] Margin Profiles and Member Engagement - The company expects to double margins despite headwinds from Star ratings, with a consistent mix of HMO and PPO plans compared to previous years [23][26] - Engagement initiatives have been enhanced, with proactive outreach to new members to improve their onboarding experience and overall satisfaction [54][56] Star Ratings and Operational Performance - Humana is optimistic about its Star Ratings performance, having made significant strides in operational metrics and member engagement [63][64] - Recent changes proposed by CMS to focus more on health outcomes rather than administrative metrics are supported by Humana, as they align with the company's ongoing efforts to improve quality [70][71] Part D and PDP Margins - Humana is guiding towards break-even margins for its Part D business, with expectations for more consistent profitability as the program stabilizes [72][74] - The company views its PDP as a strategic starter product that can lead to further engagement in MAPD plans [75] Regulatory Environment and Rate Notice - The company expressed concerns about the implications of the preliminary rate notice from CMS, emphasizing the need for adjustments to maintain benefits amidst rising costs [80][81] - Humana is actively engaging with policymakers to advocate for necessary changes that would benefit members [81] CenterWell and Acquisitions - Recent acquisitions in Florida are aimed at filling geographic gaps in Humana's CenterWell portfolio, enhancing operational fit and expanding the primary care footprint [102][103] - The company emphasizes that both the Medicare Advantage and CenterWell businesses must stand alone financially [106] Conclusion - Humana is strategically positioned to navigate the current healthcare landscape, focusing on member retention, quality improvement, and operational efficiency while adapting to regulatory changes and market dynamics. The company remains committed to its long-term financial goals and enhancing member value through targeted initiatives.

Core Viewpoint - Humana's stock experienced a significant decline of 21% following the CMS's announcement of a minimal rate increase for 2027, highlighting the company's vulnerability as a "pure play" on Medicare Advantage, which constitutes approximately 85% of its operations [2] Financial Performance - Humana's Q3 2025 revenue was reported at $32.65 billion, reflecting an 11% year-over-year increase, while adjusted EPS for the same period was $3.24, down 22% year-over-year [2] - The medical benefit ratio for Q3 2025 stood at 91.1%, indicating limited profitability potential, as ratios above 90% are generally unfavorable [3] - The company anticipates a full-year 2025 adjusted EPS of around $17.00, with a projected benefit ratio between 90.1% and 90.5% [3] Membership Trends - Humana is facing a decline in Medicare Advantage membership, with an expected loss of approximately 425,000 members in 2025 due to withdrawal from unprofitable markets [3] Star Ratings Impact - Humana's Star Ratings, which influence bonus payments from CMS, have significantly dropped for the bonus year 2027, leading to reduced reimbursements and a competitive disadvantage compared to peers like UnitedHealth [5] Valuation Insights - Following the recent stock decline, Humana is trading at around $209 per share, approximately 13 times the estimated 2026 EPS, which appears slightly undervalued compared to historical multiples of 16-18 times [6] - The company is focusing on operational efficiencies and aims to achieve over $100 million in savings through AI and outsourcing [6] Future Projections - Analysts project a loss of $4.00 per share for Q4 2025, contrasting with a loss of $2.16 in Q4 2024, reflecting the challenges in addressing the Star Ratings issue [7] - The company is implementing a "reset" strategy for 2025-2026, but its effectiveness remains unproven amid regulatory challenges [8] Investment Outlook - The investment view suggests that Humana presents a high-risk profile until Q4 results and final 2027 rates are disclosed, with a 35% analyst upside projection considered optimistic given existing structural hurdles [9]

Core Insights - Aetna, a CVS Health company, reported that over 81% of its Medicare Advantage members are enrolled in 2026 MAPD plans rated 4 stars or higher by CMS, with over 63% in 4.5-star plans [1][2] Group 1: Company Performance - Aetna's strong Star Ratings reflect its commitment to delivering exceptional care experiences and better health outcomes for Medicare Advantage members [2] - The company continues to rank among the top tier of large publicly traded companies in CMS Star Ratings, showcasing its industry leadership in high-quality Medicare solutions [2] Group 2: Specific Contracts and Achievements - Aetna Life Insurance Company's H5522 contract serves over 1.3 million Employer Group Medicare Advantage members and has achieved 4.5 stars for 14 consecutive years [7] - The H5521 contract, serving 1.1 million Individual Medicare Advantage members, also achieved 4.5 stars, maintaining its performance from the previous year [7] - Other contracts, such as H3959 and H2293, have also demonstrated strong performance with 4 and 4-star ratings respectively, highlighting Aetna's consistent quality across various plans [7]

Core Viewpoint - Clover Health Investments, Corp. emphasizes its differentiated business model and expresses confidence in achieving above-market membership growth and increasing Adjusted EBITDA profitability through 2027, independent of Star ratings [1][2]. Business Performance - Clover Health's Medicare Advantage plans received a 3.5 Star rating for its PPO plans and a 4.0 Star rating for its HMO plan from CMS for the 2026 payment year, which will affect payments in 2027 [1]. - In the first half of 2025, Clover Health experienced a 34% increase in revenue and a 32% increase in membership year-over-year, while maintaining sustained Adjusted EBITDA profitability [2]. Clinical Quality - Clover Health scored 4.72 on HEDIS clinical quality measures for its PPO plans, indicating strong performance in clinical measures, largely attributed to its Clover Assistant clinical platform [3]. Health Policy Perspective - The company argues that the Star rating system does not accurately reflect the health outcomes it delivers, as it places excessive weight on non-outcome measures rather than actual clinical results [4]. - Clover Health is actively engaging with CMS to ensure that its Star rating accurately reflects the quality of its Medicare Advantage offerings [4]. Future Outlook - The company anticipates continued strong above-market growth in Medicare Advantage and expansion of Adjusted EBITDA profitability during 2026 and 2027, driven by several strategic initiatives [6]. - Key drivers include the development of AI-powered features in Clover Assistant, increasing physician adoption, prioritizing member retention, and optimizing operating leverage [7].